Evidence map›Paper›PMID 34799365›Full record

ArticleBMJ open2021

Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland: protocol for a national observational study.

Tanja Mueller, Steven Kerr, Stuart McTaggart, Amanj Kurdi, Eleftheria Vasileiou, Annemarie Docherty, Kenny Fraser, Ting Shi, Colin R Simpson, Marion Bennie and 1 more

Abstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tanja MuellerStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK tanja.muller@strath.ac.uk.ORCID 0000-0002-0418-4789
Steven KerrUsher Institute, The University of Edinburgh, Edinburgh, UK.
Stuart McTaggartPublic Health Scotland, Edinburgh, UK.ORCID 0000-0001-6060-9019
Amanj KurdiStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.ORCID 0000-0001-5036-1988
Eleftheria VasileiouUsher Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-6850-7578
Annemarie DochertyUsher Institute, The University of Edinburgh, Edinburgh, UK.
Kenny FraserTriscribe Limited, Glasgow, UK.
Ting ShiUsher Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-4101-4535
Colin R SimpsonUsher Institute, The University of Edinburgh, Edinburgh, UK.
Marion BenniePublic Health Scotland, Edinburgh, UK.ORCID 0000-0002-4046-629X
Aziz SheikhUsher Institute, The University of Edinburgh, Edinburgh, UK.

Funding

European Research CouncilMedical Research Council MC_PC_19004Medical Research Council MC_PC_19075
6 · The paper itself

Abstract

introductionCOVID-19 has caused millions of hospitalisations and deaths globally. A range of vaccines have been developed and are being deployed at scale in the UK to prevent SARS-CoV-2 infection, which have reduced risk of infection and severe COVID-19 outcomes. Those with COVID-19 are now being treated with several repurposed drugs based on evidence emerging from recent clinical trials. However, there is currently limited real-world data available related to the use of these drugs in routine clinical practice. The purpose of this study is to address the prevailing knowledge gaps regarding the use of dexamethasone, remdesivir and tocilizumab by conducting an exploratory drug utilisation study, aimed at providing in-depth descriptions of patients receiving these drugs as well as the treatment patterns observed in Scotland. METHODS AND ANALYSIS: Retrospective cohort study, comprising adult patients admitted to hospital with confirmed or suspected COVID-19 across five Scottish Health Boards using data from in-hospital ePrescribing linked to the Early Estimation of Vaccine and Anti-Viral Effectiveness (EAVE II) COVID-19 surveillance platform. The primary outcome will be exposure to the medicines of interest (dexamethasone, remdesivir, tocilizumab), either alone or in combination; exposure will be described in terms of drug(s) of choice; prescribed and administered dose; treatment duration; and any changes in treatment, for example, dose escalation and/or switching to an alternative drug. Analyses will primarily be descriptive in nature. ETHICS AND DISSEMINATION: Ethical and information governance approvals have been obtained by the National Research Ethics Service Committee, South East Scotland 02 and the Public Benefit and Privacy Panel for Health and Social Care, respectively. Findings from this study will be presented at academic and clinical conferences, and to the funders and other interested parties as appropriate; study findings will also be published in peer-reviewed journals. Publications will be available on the EAVE II website (https://www.ed.ac.uk/usher/eave-ii/key-outputs/our-publications), alongside lay summaries and infographics aimed at the general public. Press releases will also be considered, if appropriate.

Indexed as

COVID-19AdultAntiviral AgentsHumansObservational Studies as TopicRetrospective StudiesSARS-CoV-2ScotlandAntiviral Agentsclinical pharmacologyCOVID-19therapeutics

Identifiers

PMID34799365
PMCPMC8609490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.